The United States market is pivotal for the pharmaceutical industry, accounting for over half of the sales of Roche’s pharmaceutical division, a global leader in oncology.
Swiss competitor Novartis recently revealed plans to invest 20 billion euros (23 billion dollars) in the United States over the next five years.
In a press release issued today, Roche announced that 43 billion euros would be allocated to bolster its production capacity in the United States, particularly in Kentucky, Indiana, New Jersey, Oregon, and California.
Currently, Roche operates 13 factories in the United States alongside 15 research and development centers, employing 25,000 individuals.
The pharmaceutical group highlighted that this investment is expected to generate 12,000 jobs, including approximately 6,500 in construction and 1,000 in manufacturing roles.
By 2024, Roche’s U.S. division is projected to achieve a turnover of nearly 26.5 billion euros (24.8 billion Swiss francs), making up 53.7% of the division’s global sales, according to the company.
In early trading, Roche’s shares fell by 1.68% to 251.30 Swiss francs (269.70 euros).
Sales from Roche’s diagnostics division, encompassing cancer screenings as well as COVID-19 and diabetes testing, reached 4.6 billion euros (4.3 billion Swiss francs) in North America, representing nearly 30.3% of the division’s sales.
